Season 4 - Ep.14: Risk factors and longevity in women and in men - Smartphone interference with pacemakers, ICDs
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
This episode covers:
- Cardiology This Week: A concise summary of recent studies
- Risk factors and longevity in women and in men
- Mythbusters: Smartphone interference with pacemakers, ICDs
Host: Rasha Al-Lamee
Guests: JP Carpenter, Christina Magnussen
Want to watch that episode? Go to: https://esc365.escardio.org/event/2559
Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview
Disclaimer
ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding.
The programme has not been influenced in any way by its funding partners.
This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.
All declarations of interest are listed at the end of the episode.
The ESC is not liable for any translated content of this video. The English language always prevails.
ESC TV Today uses a range of tools and resources (including AI) to support content production.
All content is reviewed and approved by the editorial team.
Statements and opinions expressed by guest speakers are their own.
Declarations of interests
Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.
Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris.
Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals.
John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.
Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.
David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll.
Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.
Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards.
Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.
Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.
Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.